Aap Implantate AG Reports Balanced EBITDA for H1/2024

aap Implantate AG achieved a balanced EBITDA for H1/2024 with significant growth in the EMEA region. Sales increased by 10% to EUR 6.4 million compared to H1/2023. The trauma division reported positive EBITDA, driving the overall performance.

The company's EBITDA for the first half of 2024 was recorded at EUR -0.0 million, a substantial improvement from EUR -1.0 million in H1/2023. This reflects strong sales growth, a high gross margin, and reduced personnel costs, especially in the USA.

Operating cash flow improved by 34% year-on-year to EUR -1.0 million. However, cash and cash equivalents decreased to EUR 0.8 million by June 30, 2024, from EUR 1.4 million at the end of 2023. Net debt decreased to EUR 1.2 million from EUR 1.8 million.

The company looks to stabilize its financial situation in H2/2024, aiming for annual revenue between EUR 11.5 million and EUR 13.5 million. EBITDA for the year is projected to be between EUR -2.5 million and EUR -1.4 million, considering costs for ongoing clinical trials.